Because XBB is relatively new, scientists are still working to figure out if and how the variant behaves differently from other recent variants. Though XBB’s symptoms are expected to be on par with past omicron infections, doctors say they are seeing some issues becoming more prevalent than others.
"You have a medication that looks to be just as good as Paxlovid, but less cumbersome," said Dr. Panagis Galiatsatos, an assistant professor of medicine at Johns Hopkins Medicine in Baltimore.
Bimodal olfactory training with visual cues and the use of patient-preferred scents did not produce a clinically meaningful improvement in sense of smell among individuals with COVID-19–related olfactory loss, a 275-patient randomized trial showed.
In this video, MedPage Today editor-in-chief Jeremy Faust, MD, sits down with allergist and immunologist Zachary Rubin, MD, of Oak Brook Allergists in Illinois, to discuss the lasting effects of COVID-19 on pediatric health.
